Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

Inclusion Criteria: 1. Patients with B-NHL,NK/T-NHL and HL were confirmed by histopathology examination had received autologous hematopoietic stem cell transplantation (including secondary transplantation). Transplantation interval was 6-8 weeks before in the study. The first diagnostic risk classification or pre-transplant disease status of each type of lymphoma is as follows: 1)B-NHL: patients who are at high risk according to the corresponding international prognostic index in the first diagnosis(IPI\>3 /aa IPI \>2 /FLIPI\>3); Patients must have received at least one first-line induction therapy but did not achieve CR or had relapse after CR; 2)NK/T-NHL: Including all patients, unlimited risk classification and pre-transplant disease status; 3)HL: Patients must have received at least one first-line induction therapy 2. Age 18-70 years, male or female; 3. ECOG performance status 0-1; 4. Organ function should fit the following : Renal function with serum creatinine \< 160μmol/L; Liver function with Total bilirubin ≤2 times of normal maximum, ALT and AST≤3 times of normal maximum. Adequate pulmonary function with forced expiratory volume at one second (FEV1), forced vital capacity (FVC) and diffusing capacity of lung for carbon monoxide (DLCO) ≥ 50% of expected corrected for hemoglobin. Adequate cardiac function with left ventricular ejection fraction ≥ 50%. No symptomatic cardiac disease; 5. Blood routine test: absolute neutrophil count ≥1.5×109/L, platelet ≥75×109/L, Hb ≥ 90g/L; 6. Life expectancy no less than 3 months; 7. Patients willing to sign the Informed Consent Form. Exclusion Criteria: 1. Patients relapsed after ASCT 2. Patients with HBsAg positive or HBcAb positive patients also detected HBV-DNA copy number positive; 3. Patients with active HCV infection; 4. Patients with active HIV infection; 5. Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulopathy, connective tissue disease, severe infectious diseases and others; 6. Patients with liver cirrhosis or evidence of liver fibrosis; 7. Patients with a QTc longer than 500 ms; 8. Patients with mental disorders or those do not have the ability to consent; 9. Patients with drug abuse, long term alcoholism that may impact the results of the trial; 10. Women during pregnancy or lactation, or fertile women unwilling to take contraceptive measures; 11. Non-appropriate patients for the trial according to the judgment of the investigators;